Subscribe to the Acquis newsletter
Combinations are not new. What is new is the velocity. The number of regimens pairing established immuno-oncology (IO) agents with novel molecules and mechanisms has grown significantly year over year, and the data supporting those pairings is maturing in ways that carry real implications for patients, drugmakers, and the broader life sciences investment thesis.
Read More
Coupa Inspire 2026 marked Coupa's 20th anniversary, and the conference reflected a company positioning itself for a new phase of growth. Coupa is building its roadmap around AI-enabled workflows, automation, and orchestration across the full spend lifecycle.
Read More
The May 2025 Most Favored Nation (MFN) executive order aims to align US drug pricing with the lowest prices paid by other developed nations. On the surface, it is a pricing policy. In practice, it is something more consequential.
Read More
Combinations are not new. What is new is the velocity. The number of regimens pairing established immuno-oncology (IO) agents with novel molecules and mechanisms has grown significantly year over year, and the data supporting those pairings is maturing in ways that carry real implications for patients, drugmakers, and the broader life sciences investment thesis.
Read More
Coupa Inspire 2026 marked Coupa's 20th anniversary, and the conference reflected a company positioning itself for a new phase of growth. Coupa is building its roadmap around AI-enabled workflows, automation, and orchestration across the full spend lifecycle.
Read More
The May 2025 Most Favored Nation (MFN) executive order aims to align US drug pricing with the lowest prices paid by other developed nations. On the surface, it is a pricing policy. In practice, it is something more consequential.
Read More
